Trade

with

Vertex Pharmaceuticals Inc
(NASDAQ: VRTX)
AdChoices
106.17
-1.99
-1.84%
After Hours :
105.23
-0.94
-0.89%

Open

109.46

Previous Close

108.16

Volume (Avg)

1.54M (1.66M)

Day's Range

106.00-111.00

52Wk Range

58.06-116.88

Market Cap.

25.28B

Dividend Rate ( Yield )

-

Beta

0.44

Shares Outstanding

238.08M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 1.21B

    • Net Income

    • -445.03M

    • Market Cap.

    • 25.28B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -56.85

    • PEG (Price/Earnings Growth) Ratio

    • 3.18

    • Beta

    • 0.44

    • Forward P/E

    • 153.85

    • Price/Sales

    • 29.67

    • Price/Book Value

    • 21.55

    • Price/Cash flow

    • -84.03

      • EBITDA

      • -855.08M

      • Return on Capital %

      • -20.06

      • Return on Equity %

      • -37.81

      • Return on Assets %

      • -20.06

      • Book Value/Share

      • 4.92

      • Shares Outstanding

      • 238.08M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 111.67

        • Credit Rating

        • BBB

        • Analysts

        • 9

        • EPS Estimate

        • 0.58

        • Cashflow Estimate

        • 0.42

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -55.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 47.18

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 90.07

            • 82.75

            • Pre-Tax Margin

            • -103.65

            • 39.38

            • Net Profit Margin

            • -56.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 88.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -239.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.44

              • 0.76

              • Current Ratio

              • 3.71

              • 2.92

              • Quick Ratio

              • 3.58

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.81

              • 2.21

              • Book Value/Share

              • 4.92

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -51.55

                • 277.78

                • P/E Ratio 5-Year High

                • -57.53

                • 634.30

                • P/E Ratio 5-Year Low

                • -13.04

                • 124.82

                • Price/Sales Ratio

                • 29.33

                • 9.35

                • Price/Book Value

                • 21.28

                • 8.50

                • Price/Cash Flow Ratio

                • -84.03

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -37.81

                    (-47.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -20.06

                    (-21.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -27.50

                    (-34.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 5.23

                  • 1.48

                  • Asset Turnover

                  • 0.35

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -903.45M
                  Operating Margin
                  -74.54
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -84.03
                  Ownership

                  Institutional Ownership

                  98.94%

                  Top 10 Institutions

                  55.02%

                  Mutual Fund Ownership

                  68.62%

                  Float

                  88.64%

                  5% / Insider Ownership

                  0.85%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    11,807,500

                  • 1.54

                  • 4.98

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    10,105,600

                  • -2.98

                  • 4.24

                  • VA CollegeAmerica Fundamental Investors

                  •  

                    5,800,000

                  • -6.68

                  • 2.44

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    5,331,394

                  • 0.00

                  • 2.24

                  • Vanguard Mid-Cap Index Fund

                  •  

                    4,072,950

                  • 1.90

                  • 1.71

                  • Vanguard Total Stock Mkt Idx

                  •  

                    3,893,770

                  • 1.66

                  • 1.64

                  • VA CollegeAmerica New Perspective

                  •  

                    3,691,000

                  • 0.00

                  • 1.55

                  • American Funds NVIT Growth

                  •  

                    3,348,700

                  • 0.00

                  • 1.41

                  • Harbor Capital Appreciation Fund

                  •  

                    3,141,912

                  • -1.40

                  • 1.32

                  • T. Rowe Price Growth Stock Fund

                  •  

                    3,017,800

                  • 10.79

                  • 1.27

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Capital World Investors

                  •  

                    26,382,177

                  • -1.34%

                  • 11.12

                  • Vanguard Group, Inc.

                  •  

                    16,702,746

                  • +1.92%

                  • 7.04

                  • Wellington Management Company, LLP

                  •  

                    16,461,104

                  • +1.10%

                  • 6.94

                  • T. Rowe Price Associates, Inc.

                  •  

                    13,866,784

                  • +17.27%

                  • 5.84

                  • Fidelity Management and Research Company

                  •  

                    12,984,419

                  • +97.34%

                  • 5.47

                  • Jennison Associates LLC

                  •  

                    11,865,009

                  • -5.86%

                  • 5.00

                  • State Street Corp

                  •  

                    9,961,924

                  • -1.31%

                  • 4.20

                  • J.P. Morgan Investment Management Inc.

                  •  

                    7,723,279

                  • +56.45%

                  • 3.25

                  • ClearBridge Advisors, LLC

                  •  

                    7,549,418

                  • +4.02%

                  • 3.18

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    7,071,330

                  • -12.98%

                  • 2.98

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Large Growth

                  Vertex Pharmaceuticals Inc was incorporated in Massachusetts in 1989. The Company is engaged in the business of discovering, developing and commercializing small molecule drugs. The Company’s two products are INCIVE (telaprevir), whi...morech is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved produc...morets and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. The Company face competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.lessless

                  Key People

                  Dr. Jeffrey M Leiden M.D.,PhD

                  CEO/Chairman of the Board/Director/President

                  Dr. Joshua S. Boger,PhD

                  Director/Founder

                  Mr. Ian F. Smith

                  Executive VP/CFO

                  Dr. Peter Mueller,PhD

                  Chief Scientific Officer/Executive VP, Divisional

                  Kenneth L. Horton

                  Executive VP/Other Executive Officer/Secretary

                  • Vertex Pharmaceuticals Inc

                  • 50 Northern Avenue

                  • Boston, MA 02210

                  • USA.Map

                  • Phone: +1 617 341-6100

                  • Fax: -

                  • vrtx.com

                  Incorporated

                  1989

                  Employees

                  1,800

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: